APYX Apyx Medical Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 719135 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.4%
TTM net income YoY42.0%
TTM EPS YoY—
Revenue 3-yr CAGR5.8%
Net income 3-yr CAGR—
Margins
Gross margin63.4%
Operating margin-5.5%
Net margin-14.2%
FCF margin-14.9%
EBITDA margin-4.1%
Returns
ROE-109.0%
ROA-14.2%
ROIC (approx.)-14.9%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets83.7%
Debt / equity3.69x
Current ratio4.95x
Interest coverage-0.59x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.03M | $13.88M | $12.49M | $19.16M | $12.88M | $11.37M | $9.43M | $14.22M |
| Cost of revenue | $5.03M | $5.01M | $4.57M | $7.17M | $4.58M | $4.29M | $3.77M | $5.26M |
| Gross profit | $9.00M | $8.87M | $7.92M | $12.00M | $8.30M | $7.08M | $5.67M | $8.96M |
| R&D expense | $849,000 | $793,000 | $765,000 | $944,000 | $801,000 | $824,000 | $804,000 | $1.12M |
| SG&A expense | $3.98M | $5.29M | $3.58M | $4.62M | $3.82M | $4.26M | $3.47M | $4.83M |
| Operating income | -$571,000 | -$1.81M | -$911,000 | $11,000 | -$832,000 | -$2.57M | -$3.05M | -$3.05M |
| Interest expense | $1.41M | $1.39M | $1.37M | $1.41M | $1.41M | $1.39M | $1.38M | $1.65M |
| Pretax income | -$1.69M | -$2.95M | -$2.00M | -$1.15M | -$1.88M | -$3.69M | -$4.12M | -$4.57M |
| Income tax | $116,000 | $124,000 | $143,000 | $94,000 | $78,000 | $49,000 | $49,000 | $89,000 |
| Net income | -$1.78M | -$3.24M | -$2.11M | -$1.30M | -$1.98M | -$3.78M | -$4.15M | -$4.63M |
| EBITDA | -$384,000 | -$1.61M | -$709,000 | $232,000 | -$668,000 | -$2.44M | -$2.91M | -$2.91M |
| EPS (basic) | -0.04 | -0.07 | -0.05 | — | -0.05 | -0.09 | -0.10 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $25.78M | $27.62M | $31.14M | $31.74M | $25.14M | $29.30M | $31.01M | $31.74M |
| Receivables | $14.87M | $13.61M | $12.76M | $16.78M | $12.99M | $11.25M | $11.64M | $15.48M |
| Inventory | $11.95M | $10.75M | $9.54M | $8.60M | $9.14M | $8.19M | $7.68M | $7.56M |
| Current assets | $53.84M | $53.16M | $54.80M | $58.47M | $48.79M | $49.91M | $51.85M | $56.44M |
| PP&E, net | $2.19M | $2.11M | $2.23M | $2.37M | $2.39M | $2.05M | $1.91M | $1.99M |
| Total assets | $61.67M | $61.07M | $63.02M | $66.84M | $57.37M | $58.19M | $60.16M | $64.84M |
| Current liabilities | $10.87M | $9.35M | $9.45M | $11.70M | $10.98M | $10.57M | $9.51M | $10.72M |
| Long-term debt | $35.57M | $35.33M | $35.09M | $34.85M | $34.61M | $34.37M | $34.13M | $33.89M |
| Total debt | $35.57M | $35.33M | $35.09M | $34.85M | $34.61M | $34.37M | $34.13M | $33.89M |
| Total liabilities | $51.63M | $49.98M | $49.94M | $52.01M | $51.28M | $50.73M | $49.52M | $50.51M |
| Shareholders' equity | $9.63M | $10.66M | $12.83M | $14.54M | $5.85M | $7.25M | $10.51M | $14.21M |
| Net debt | $9.80M | $7.71M | $3.95M | $3.11M | $9.47M | $5.06M | $3.12M | $2.15M |
| Shares outstanding | 42.12M | 42.12M | 41.87M | 41.79M | 37.82M | 37.79M | 37.79M | 37.79M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.63M | -$3.49M | -$572,000 | -$2.53M | -$3.54M | -$1.23M | -$702,000 | -$2.94M |
| Capital expenditure | $265,000 | $66,000 | $60,000 | $275,000 | $519,000 | $265,000 | $55,000 | $245,000 |
| Free cash flow | -$1.90M | -$3.56M | -$632,000 | -$2.81M | -$4.05M | -$1.50M | -$757,000 | -$3.18M |
| Investing cash flow | -$265,000 | -$66,000 | -$60,000 | -$275,000 | -$519,000 | -$265,000 | -$55,000 | -$245,000 |
| Financing cash flow | -$5,000 | -$5,000 | $83,000 | $9.48M | $45,000 | $25,000 | $25,000 | $6.76M |
| Depreciation & amortization | $187,000 | $196,000 | $202,000 | $221,000 | $164,000 | $132,000 | $138,000 | $142,000 |
| Stock-based compensation | $753,000 | $1.07M | $312,000 | $500,000 | $530,000 | $520,000 | $451,000 | $838,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.